QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:GRFS

Grifols (GRFS) Stock Forecast, Price & News

$9.16
-0.03 (-0.33%)
(As of 09/26/2023 ET)
Compare
Today's Range
$9.14
$9.28
50-Day Range
$8.91
$10.91
52-Week Range
$5.71
$10.97
Volume
195,979 shs
Average Volume
812,283 shs
Market Capitalization
$6.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Grifols MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
107.4% Upside
$19.00 Price Target
Short Interest
Healthy
1.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Grifols in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
72.73%
From $0.66 to $1.14 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

626th out of 964 stocks

Pharmaceutical Preparations Industry

278th out of 446 stocks


GRFS stock logo

About Grifols (NASDAQ:GRFS) Stock

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

GRFS Price History

GRFS Stock News Headlines

Grifols: Cheap For A Reason
Grifols SA (OZTA.MU)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
GRFS or STVN: Which Is the Better Value Stock Right Now?
Grifols SA ADR GRFS Stock Quote
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Kepler Capital Sticks to Their Buy Rating for Grifols SA (GRFS)
Grifols S.A. Q2 2023 Earnings Preview
Should Value Investors Buy Grifols (GRFS) Stock?
Grifols: A Promising Buy Opportunity
Grifols (NASDAQ: GRFS)
Grifols SA Pref (GRLSbn)
See More Headlines
Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

GRFS Company Calendar

Last Earnings
7/27/2023
Today
9/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRFS
Employees
26,314
Year Founded
1909

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+106.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.39 billion
Cash Flow
$0.92 per share
Book Value
$12.96 per share

Miscellaneous

Free Float
686,249,000
Market Cap
$6.33 billion
Optionable
Optionable
Beta
0.47

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Thomas H. Glanzmann (Age 65)
    CEO & Exec. Chairman
    Comp: $160.08k
  • Mr. Raimon Grifols Roura (Age 59)
    Chief Corp. Officer & Vice-Chairman
    Comp: $1.11M
  • Mr. Víctor Grifols Deu (Age 46)
    COO & Director
    Comp: $1.11M
  • Mr. Alfredo Arroyo Guerra (Age 65)
    CFO & VP
  • Mrs. Eva Bastida Tubau
    Corp. VP and Director of Scientific & Medical Affairs
  • Ms. Nuria Pascual Lapeña (Age 59)
    VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer
  • Mr. David Ian Bell (Age 69)
    Chief Corp. Devel., Legal & Data Protection Officer
  • Mr. Mateo Florencio Borrás Humbert (Age 67)
    Corp. VP & Chief HR Officer
  • Ms. Maria Teresa-Rioné Llano (Age 58)
    Chief Communications Officer
  • Ms. Montserrat Gaja Llamas (Age 58)
    Chief HR Officer













GRFS Stock - Frequently Asked Questions

Should I buy or sell Grifols stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GRFS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRFS, but not buy additional shares or sell existing shares.
View GRFS analyst ratings
or view top-rated stocks.

What is Grifols' stock price forecast for 2023?

6 equities research analysts have issued 1 year target prices for Grifols' shares. Their GRFS share price forecasts range from $9.00 to $13.00. On average, they expect the company's stock price to reach $10.67 in the next year. This suggests a possible upside of 15.9% from the stock's current price.
View analysts price targets for GRFS
or view top-rated stocks among Wall Street analysts.

How have GRFS shares performed in 2023?

Grifols' stock was trading at $8.50 at the start of the year. Since then, GRFS shares have increased by 8.2% and is now trading at $9.20.
View the best growth stocks for 2023 here
.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) issued its quarterly earnings results on Thursday, July, 27th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter. The biotechnology company earned $1.81 billion during the quarter.

What ETF holds Grifols' stock ?

First Trust NYSE Arca Biotechnology Index Fund holds 4,612,158 shares of GRFS stock, representing 3.48% of its portfolio.

When did Grifols' stock split?

Shares of Grifols split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Grifols own?
What is Grifols' stock symbol?

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Who are Grifols' major shareholders?

Grifols' stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital World Investors (2.84%), Black Creek Investment Management Inc. (1.20%), Harris Associates L P (0.40%), BlackRock Inc. (0.32%), Point72 Asset Management L.P. (0.28%) and Goldman Sachs Group Inc. (0.21%).

How do I buy shares of Grifols?

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Grifols' stock price today?

One share of GRFS stock can currently be purchased for approximately $9.20.

How much money does Grifols make?

Grifols (NASDAQ:GRFS) has a market capitalization of $6.33 billion and generates $6.39 billion in revenue each year.

How many employees does Grifols have?

The company employs 26,314 workers across the globe.

Does Grifols have any subsidiaries?
The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..
Read More
How can I contact Grifols?

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The official website for the company is www.grifols.com. The biotechnology company can be reached via phone at (493) 571-0221, via email at inversores@grifols.com, or via fax at 34-93-571-0267.

This page (NASDAQ:GRFS) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -